Monographie - Etoposide

Etoposide

Formula chimica

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eposin	Africa de Sud, Belgia, Columbia, Malaezia, Marea Britanie, Norvegia, Suedia
Etocris	Argentina, Chilli, Peru
Etolon	India
Etomedac	Germania, Luxemburg
Etonolver	Venezuela
Etoposide	Franta, Grecia, Olanda
Etosid	Egipt, India, Malaezia
Eunades	Brazilia
Euvaxon	Argentina
Exitop	Finlanda, Germania, Suedia
Fytosid	Egipt, India, Malaezia
Lastet	Egipt, Emiratele Arabe Unite, Iran, Italia, Polonia, Turcia, Ungaria
Onkoposid	Germania
Riboposid	Germania
Sedol	Peru
Toposin	Olanda
Tosuben	Mexic
Vepesid	Africa de Sud, Arabia Saudita, Australia, Austria, Belgia, Canada, Columbia, Croatia, Danemarca, Egipt, Elvetia, Finlanda, Germania, Grecia, Irlanda, Italia, Luxemburg, Olanda, Polonia, Slovenia, Spania, SUA, Turcia, Ungaria
Vepeside	Maroc, Tunisia

Bibliografie : Etoposide

	Tip	Publicare
3	Ziar	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57	Ziar	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Ziar	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Ziar	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Ziar	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Ziar	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Ziar	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
140	Ziar	Pearson SD, Trissel LA. Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 1993 ; 50: 1405-1409.
150	Ziar	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	Ziar	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
161	Ziar	Barthes DM, Rochard EB, Pouliquen IJ, Rabouan SM, Courtois PY. Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers. Am J Hosp Pharm 1994 ; 51: 2706-2709.
169	Ziar	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Ziar	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
184	Ziar	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Ziar	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Ziar	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Ziar	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	Ziar	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Ziar	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Ziar	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Ziar	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
417	Ziar	Stewart CF, Hampton EM. Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 1400-1404.
482	Ziar	Beijnen JH, Beijnen-Bandhoe U, Dubbelman AC, Van Gijn R, Underberg WJM. Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. J Parenter Sci Technol 1991 ; 45: 108-112.
491	Ziar	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Ziar	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
504	Ziar	Hamon M, Plas-Remoissenet D, Kubab-Alajati S. Etude de la stabilité dans des solutions diluées destinées à la perfusion de deux antimitotiques dérivés de la podophyllotoxine : l’étoposide (VP 16), le téniposide (VM 26). Sci Tech Pharm 1987 ; 3: 33-40.
643	Ziar	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
905	Ziar	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1026	Ziar	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033	Ziar	Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1999 ; 56: 985-989.
1423	Ziar	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Ziar	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Laborator	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1613	Ziar	Lepage R, Walker SE, Godin J. Stability and compatibility of etoposide in normal saline. Can J Hosp Pharm 2000 ; 53: 338-345.
1722	Ziar	Gras C, Sautou-Miranda V, Bagel-Boithias S, Brigas F, Chopineau J. Compatibility of etoposide solution with polyvinyl chloride and low density polyethylene containers and its stability in different storage conditions. EJHP 2002 ; 2: 33-40.
1730	Ziar	Björkman S, Roth B. Chemical compatibility of mitoxantrone and etoposide (VP-16). Act Pharm Nord 1991 ; 3: 251.
1819	Ziar	Demoré B, Vigneron J, Perrin A, Hoffman MA, Hoffman M. Leaching of diethyl hexyl phtalate from polyvinyl chloride bags into intravenous etoposide solution. J Clin Pharm Ther 2002 ; 27: 139-142.
1895	Ziar	Bourdeaux D, Sautou-Miranda V, Bagel-Boithias S, Boyer A, Chopineau J. Analysis by liquid chromatography and infrared spectrometry of di(2-ethylhexyl)phtalate released by multilayer infusion tubing. J Pharm Biomed Anal 2004 ; 35: 57-64.
1984	Ziar	Bagel-Boithias S, Sautou-Miranda V, Bourdeaux D, Tramier V, Boyer A, Chopineau J. Leaching of diethylhexyl phtalate from multilayer tubing into etoposide infusion solutions. Am J Health-Syst Pharm 2005 ; 62: 182-188.
2108	Ziar	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2167	Ziar	Joel SP, Clark PI, Slevin ML. Stability of the iv and oral formulations of etoposide in solution. Cancer Chemother Pharmacol 1995 ; 37, 1: 117-124.
3574	Laborator	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3670	Ziar	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
4024	Poster	Sadou Yaye H, Rieber Z, HassaniI L, Hoffmann-Martinot C, Babiard M, Aouti H, Bellanger A, Tilleul P. Pénurie mondiale d'Etopophos et conséquences pratiques : Intérêt des études de stabilité dans le choix d'un générique. SFPO Congress 2017 - Nantes 2017
4125	Ziar	D'Huart E, Vigneron J, Lider P, Demoré B. Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags. EJHP 2020 ; 27, 1: 43-48.
4304	Ziar	Klasen K, Kessari R, Mercier L, Valade C, Grill J, Desmaris R, Paci A. Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices. Drugs R D 2014 ; 14:13?23.
4352	Ziar	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.
4369	Ziar	Sadou Yayé H, Hassani L, Secrétan PH, Babiard M, Aouati H, Bellanger A, Tilleul P, Yagoubi N, Do B, Rietveld I. Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate J Pharm Biomed Anal 2020 ;178:112896